Given that SARS-CoV-2 is predominantly a respiratory
pathogen, could a nebulized vaccine be more effective in terms of
bioavailability and function?
Single-domain antibodies have been investigated as potential
therapeutics for influenza, RSV and HIV in addition to coronaviruses.
SARS-CoV-2 mainly targets the respiratory tract, hence the development
of vaccines directed to the respiratory epithelia and lung parenchyma
using a nebulizer has been considered to maximize bioavailability and
function.207 Although active research against
respiratory viruses has focused on aerosolized plasmid DNA vaccines,
other forms of vaccine administration are currently further advanced in
clinical trials.203 Veterinary medicine commonly uses
aerosolized coronavirus vaccines for chicken farms.208